<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32924269</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1582-4934</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>24</Volume>
            <Issue>20</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of cellular and molecular medicine</Title>
          <ISOAbbreviation>J Cell Mol Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Mutations in the notch signalling pathway are associated with enhanced anti-tumour immunity in colorectal cancer.</ArticleTitle>
        <Pagination>
          <StartPage>12176</StartPage>
          <EndPage>12187</EndPage>
          <MedlinePgn>12176-12187</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jcmm.15867</ELocationID>
        <Abstract>
          <AbstractText>The Notch signalling pathway is involved in the development of several cancers, including colorectal cancer (CRC). However, whether mutations in this pathway could alter the CRC immunophenotype remains unknown. Here, we investigated the relationship between Notch signalling pathway mutations and the tumour immune microenvironment by analysing gene expression data from the GSE108989 single T cell RNA sequencing data set and The Cancer Genome Atlas (TCGA) data set. We found that Notch signalling pathway mutations were associated with an increased number of tumour-specific CD8<sup>+</sup> T cells and decreased number of inhibitory regulatory T (Treg) cells, representing an enhanced anti-tumour response in the GSE108989 data set. In TCGA data set, we also found that Notch signalling pathway mutations were associated with enrichment of genes associated with immune activation pathways and higher expressions of PDCD1, GZMB and PRF1. Although Notch signalling pathway mutations did not affect the overall survival and disease-free survival of CRC patients, they were associated with earlier disease stages and lower rates of metastasis. These results demonstrated that Notch signalling pathway mutations can enhance anti-tumour immunity in CRC, as validated by the two data sets, suggesting that they may be promising biomarkers for immune checkpoint blockade therapies for CRC patients.</AbstractText>
          <CopyrightInformation>© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Fei</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Long</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Chronic Disease Laboratory, Institutes for Life Sciences, South China University of Technology, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Immunology and School of Life Sciences, University of Science and Technology of China, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Liang</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Chronic Disease Laboratory, Institutes for Life Sciences, South China University of Technology, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Zhi-Bin</ForeName>
            <Initials>ZB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Chronic Disease Laboratory, Institutes for Life Sciences, South China University of Technology, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Fang</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yao</LastName>
            <ForeName>Yuan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qiu</LastName>
            <ForeName>Wen-Jing</ForeName>
            <Initials>WJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Zi-Xin</ForeName>
            <Initials>ZX</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Qing-Qing</ForeName>
            <Initials>QQ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Quan</LastName>
            <ForeName>Yi-Bo</ForeName>
            <Initials>YB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lian</LastName>
            <ForeName>Zhe-Xiong</ForeName>
            <Initials>ZX</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Chronic Disease Laboratory, Institutes for Life Sciences, South China University of Technology, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cao</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-0401-590X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>09</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Cell Mol Med</MedlineTA>
        <NlmUniqueID>101083777</NlmUniqueID>
        <ISSNLinking>1582-1838</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003602" MajorTopicYN="N">Cytotoxicity, Immunologic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007109" MajorTopicYN="Y">Immunity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016246" MajorTopicYN="N">Lymphocytes, Tumor-Infiltrating</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051880" MajorTopicYN="N">Receptors, Notch</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">anti-tumour immunity</Keyword>
        <Keyword MajorTopicYN="Y">colorectal cancer</Keyword>
        <Keyword MajorTopicYN="Y">mutation</Keyword>
        <Keyword MajorTopicYN="Y">notch signalling pathway</Keyword>
        <Keyword MajorTopicYN="Y">tumour microenvironment</Keyword>
      </KeywordList>
      <CoiStatement>The authors confirm that there are no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32924269</ArticleId>
        <ArticleId IdType="pmc">PMC7579712</ArticleId>
        <ArticleId IdType="doi">10.1111/jcmm.15867</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394‐424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30207593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor‐infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer‐Am Cancer Soc. 2001;91(12):2417‐2422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11413533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Le DT, Uram JN, Wang H, et al. PD‐1 blockade in tumors with mismatch‐repair deficiency. N Engl J Med. 2015;372(26):2509‐2520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4481136</ArticleId>
            <ArticleId IdType="pubmed">26028255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Saeterdal I, Bjorheim J, Lislerud K, et al. Frameshift‐mutation‐derived peptides as tumor‐specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A. 2001;98(23):13255‐13260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC60857</ArticleId>
            <ArticleId IdType="pubmed">11687624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006;7(9):678‐689.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16921404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Radtke F, Fasnacht N, Macdonald HR. Notch signaling in the immune system. Immunity. 2010;32(1):14‐27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20152168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Axelrod JD, Matsuno K, Artavanis‐Tsakonas S, Perrimon N. Interaction between Wingless and Notch signaling pathways mediated by dishevelled. Science. 1996;271(5257):1826‐1832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8596950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Guo M, Jan LY, Jan YN. Control of daughter cell fates during asymmetric division: interaction of Numb and Notch. Neuron. 1996;17(1):27‐41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8755476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhong W, Feder JN, Jiang MM, Jan LY, Jan YN. Asymmetric localization of a mammalian numb homolog during mouse cortical neurogenesis. Neuron. 1996;17(1):43‐53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8755477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang L, Yu X, Zheng L, et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature. 2018;564(7735):268‐272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30479382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Senbabaoglu Y, Gejman RS, Winer AG, et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 2016;17(1):231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5114739</ArticleId>
            <ArticleId IdType="pubmed">27855702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Charoentong P, Finotello F, Angelova M, et al. Pan‐cancer immunogenomic analyses reveal genotype‐immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248‐262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28052254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen‐specific CD8 T cells infiltrating the tumor express high levels of PD‐1 and are functionally impaired. Blood. 2009;114(8):1537‐1544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2927090</ArticleId>
            <ArticleId IdType="pubmed">19423728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gros A, Robbins PF, Yao X, et al. PD‐1 identifies the patient‐specific CD8(+) tumor‐reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124(5):2246‐2259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4001555</ArticleId>
            <ArticleId IdType="pubmed">24667641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sawant DV, Yano H, Chikina M, et al. Adaptive plasticity of IL‐10(+) and IL‐35(+) Treg cells cooperatively promotes tumor T cell exhaustion. Nat Immunol. 2019;20(6):724‐735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6531353</ArticleId>
            <ArticleId IdType="pubmed">30936494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Turnis ME, Sawant DV, Szymczak‐Workman AL, et al. Interleukin‐35 limits anti‐tumor immunity. Immunity. 2016;44(2):316‐329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4758699</ArticleId>
            <ArticleId IdType="pubmed">26872697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Doebbeler M, Koenig C, Krzyzak L, et al. CD83 expression is essential for Treg cell differentiation and stability. JCI Insight. 2018;3(11):e99712.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6124443</ArticleId>
            <ArticleId IdType="pubmed">29875316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Noah TK, Shroyer NF. Notch in the intestine: regulation of homeostasis and pathogenesis. Annu Rev Physiol. 2013;75:263‐288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23190077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Irshad S, Bansal M, Guarnieri P, et al. Bone morphogenetic protein and Notch signalling crosstalk in poor‐prognosis, mesenchymal‐subtype colorectal cancer. J Pathol. 2017;242(2):178‐192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5488238</ArticleId>
            <ArticleId IdType="pubmed">28299802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chu D, Wang W, Xie H, et al. Notch1 expression in colorectal carcinoma determines tumor differentiation status. J Gastrointest Surg. 2009;13(2):253‐260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18777195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chu D, Li Y, Wang W, et al. High level of Notch1 protein is associated with poor overall survival in colorectal cancer. Ann Surg Oncol. 2010;17(5):1337‐1342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20058190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sonoshita M, Aoki M, Fuwa H, et al. Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling. Cancer Cell. 2011;19(1):125‐137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21251616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rodilla V, Villanueva A, Obrador‐Hevia A, et al. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad Sci U S A. 2009;106(15):6315‐6320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2669348</ArticleId>
            <ArticleId IdType="pubmed">19325125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jackstadt R, van Hooff SR, Leach JD, et al. Epithelial NOTCH signaling rewires the tumor microenvironment of colorectal cancer to drive poor‐prognosis subtypes and metastasis. Cancer Cell. 2019;36(3):319‐336.e7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6853173</ArticleId>
            <ArticleId IdType="pubmed">31526760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ntziachristos P, Lim JS, Sage J, Aifantis I. From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell. 2014;25(3):318‐334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4040351</ArticleId>
            <ArticleId IdType="pubmed">24651013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Colombo M, Mirandola L, Chiriva‐Internati M, et al. Cancer cells exploit notch signaling to redefine a supportive cytokine milieu. Front Immunol. 2018;9:1823.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6102368</ArticleId>
            <ArticleId IdType="pubmed">30154786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rutz S, Janke M, Kassner N, et al. Notch regulates IL‐10 production by T helper 1 cells. Proc Natl Acad Sci U S A. 2008;105(9):3497‐3502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2265185</ArticleId>
            <ArticleId IdType="pubmed">18292228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Asano N, Watanabe T, Kitani A, Fuss IJ, Strober W. Notch1 signaling and regulatory T cell function. J Immunol. 2008;180(5):2796‐2804.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18292500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lin JT, Wang JY, Chen MK, et al. Colon cancer mesenchymal stem cells modulate the tumorigenicity of colon cancer through interleukin 6. Exp Cell Res. 2013;319(14):2216‐2229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23751564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shen Q, Cohen B, Zheng W, et al. Notch shapes the innate immunophenotype in breast cancer. Cancer Discov. 2017;7(11):1320‐1335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28790030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mirandola L, Apicella L, Colombo M, et al. Anti‐Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF‐1. Leukemia. 2013;27(7):1558‐1566.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23354012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Groom JR, Luster AD. CXCR3 in T cell function. Exp Cell Res. 2011;317(5):620‐631.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3065205</ArticleId>
            <ArticleId IdType="pubmed">21376175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rashighi M, Agarwal P, Richmond JM, et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014;6(223):223ra23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4086941</ArticleId>
            <ArticleId IdType="pubmed">24523323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Luster AD, Leder P. IP‐10, a ‐C‐X‐C‐ chemokine, elicits a potent thymus‐dependent antitumor response in vivo. J Exp Med. 1993;178(3):1057‐1065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2191174</ArticleId>
            <ArticleId IdType="pubmed">8350046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mikucki ME, Fisher DT, Matsuzaki J, et al. Non‐redundant requirement for CXCR3 signalling during tumoricidal T‐cell trafficking across tumour vascular checkpoints. Nat Commun. 2015;6:7458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4605273</ArticleId>
            <ArticleId IdType="pubmed">26109379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chow MT, Ozga AJ, Servis RL, et al. Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti‐PD‐1 Therapy. Immunity. 2019;50(6):1498‐1512.e5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6527362</ArticleId>
            <ArticleId IdType="pubmed">31097342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Miyamoto Y, Maitra A, Ghosh B, et al. Notch mediates TGF alpha‐induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell. 2003;3(6):565‐576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12842085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stylianou S, Clarke RB, Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Res. 2006;66(3):1517‐1525.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16452208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Santagata S, Demichelis F, Riva A, et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res. 2004;64(19):6854‐6857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15466172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gao J, Chen C, Hong L, et al. Expression of Jagged1 and its association with hepatitis B virus X protein in hepatocellular carcinoma. Biochem Biophys Res Commun. 2007;356(2):341‐347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17359939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ramdass B, Maliekal TT, Lakshmi S, et al. Coexpression of Notch1 and NF‐kappaB signaling pathway components in human cervical cancer progression. Gynecol Oncol. 2007;104(2):352‐361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17098279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Konishi J, Kawaguchi KS, Vo H, et al. Gamma‐secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res. 2007;67(17):8051‐8057.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17804716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hopfer O, Zwahlen D, Fey MF, Aebi S. The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer. 2005;93(6):709‐718.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2361628</ArticleId>
            <ArticleId IdType="pubmed">16136053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sjolund J, Johansson M, Manna S, et al. Suppression of renal cell carcinoma growth by inhibition of Notch signalling in vitro and in vivo. J Clin Invest. 2008;118(1):217‐228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2129233</ArticleId>
            <ArticleId IdType="pubmed">18079963</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
